Navigation Links
ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results
Date:2/28/2012

ned our early stage and commercial pipeline through four separate strategic business development agreements.  In 2012, our focus will remain on enhancing brand loyalty for patients who rely on our products, continuing the globalization of our product portfolio, and meeting the evolving needs of patients suffering from serious medical conditions."

Our GAAP net income was $53.2 million in the fourth quarter of 2011 compared to $37.5 million in the 2010 fourth quarter.  GAAP diluted earnings per share was $0.65 for the fourth quarter of 2011 compared to $0.43 for the same period in 2010. For the full year in 2011, GAAP net income was $140.7 million compared to $125.6 million of GAAP net income during 2010.  GAAP diluted earnings per share was $1.68 for the full year 2011 compared to $1.47 during 2010.

Non-GAAP adjusted net income for the three and twelve months ended December 31, 2011 was $50.6 million and $181.9 million, respectively, compared to $45.3 million and $156.3 million for the same periods in 2010.  Non-GAAP adjusted diluted earnings per share was $0.61 for the fourth quarter of 2011 compared to $0.50 for the same period in 2010.  Non-GAAP adjusted diluted earnings per share was $2.09 for the full year 2011 compared to $1.76 for the full year 2010.  A reconciliation between GAAP and non-GAAP adjusted measures is provided in the Selected Financial Information – Non-GAAP Financial Measures Reconciliation table included with this release.  

Operating HighlightsCinryze net sales during the three and twelve months ended December 31, 2011 were $66.7 million and $251.2 million, respectively, a 27 percent and 42 percent increase over the respective periods in 2010 due to an increase in the number of patients receiving Cinryze. Vancocin net sales during the three and twelve months ended December 31, 2011 were $77.8 million and $288.9 million, respectively, or a 15 percent and 11 percent increase
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. ViroPharma to Present at Three September Healthcare Conferences
2. ViroPharma to Present at Three October Healthcare Conferences
3. ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
4. ViroPharma Enhances Leadership to Support Global Growth and Expanding Business
5. ViroPharma to Present at Three November Healthcare Conferences
6. ViroPharma Incorporated Reports Fourth Quarter and Full Year 2008 Financial Results
7. ViroPharma Improves Financial Position Through Repurchase of $45 Million Principal Amount of Senior Convertible Notes
8. ViroPharma to Release 2009 First Quarter Financial Results on April 29, 2009
9. ViroPharma Incorporated Reports First Quarter 2009 Financial Results
10. ViroPharma Incorporated Honored by the National Organization for Rare Disorders
11. ViroPharma to Present at Two June Healthcare Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 ... into law H.R. 83, the Omnibus and Continuing ... first time, made hydrocephalus a condition eligible to ... Programs (CDMRP) administered by the Department of Defense ... with its allies on Capitol Hill, is celebrating ...
(Date:12/24/2014)... The report expects global cell isolation and ... also provides a carefully analyzed data about the vital ... market. , Full Copy of Report @ http://bit.ly/1yUxy0T ... for cell expansion will keep witnessing growth at an ... to be driven by rapid technological advancements, government funding ...
(Date:12/24/2014)... LONDON , December 23, 2014 ... Review Algeria , out today and available for free ... the actors driving change and growth in the sector today. ... has scored notable successes has been in developing a homegrown ... 70 percent local production still remains some way off. A ...
(Date:12/22/2014)... (PRWEB) December 22, 2014 The ... global leader of technical training across the life sciences ... Data Management (SCDM) to provide the organization's members ... programs —providing access to the more than 350 sessions ... members with 10% off when registering for a ...
Breaking Biology Technology:Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3PharmaBoardroom Releases New Algeria Pharmaceuticals Report 2PharmaBoardroom Releases New Algeria Pharmaceuticals Report 3CfPIE Announces Partnership with the Society for Clinical Data Management 2CfPIE Announces Partnership with the Society for Clinical Data Management 3
... LAVAL, QC, Sept. 12 /PRNewswire-FirstCall/ - The ... Inc. (NASDAQ.NEPT - TSX.V.NTB) decided,not to re-price ... owned by officers and directors., About ... proprietary bioactive ingredients and,products for nutraceutical and ...
... Sept. 12 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer ... of Mr. Jindong Zhou,and Mr. Xiaojin Yin to ... the appointment of Mr. Qingsen Li to the ...
... LIVERMORE, Calif. - Researchers have achieved a milestone ... a high-resolution snapshot of the transformation of nanoscale ... Microscope (DTEM), Judy Kim and colleagues peered into ... (also known as nanolaminates) with 15-nanosecond-scale resolution. , ...
Cached Biology Technology:Neptune Technologies decided not to re-price options 2Simcere Pharmaceutical Group Announces Two Senior Promotions and Appointment of New Vice President of Human Resources 2A snapshot of the transformation 2
(Date:12/11/2014)... ST. PAUL, Minn. , Dec. 10, 2014 ... in wireless physiologic monitoring, has released a new ... changing needs of preclinical toxicology researchers. M series, ... to help toxicologists collect the best possible physiologic ... studies. Adding functional endpoints to toxicology ...
(Date:12/10/2014)... WINSTON-SALEM, N.C. , Dec. 9, 2014  Wake Forest ... medical education building for its School of Medicine. Funding ... a larger capital campaign that will be publicly launched ... will be located in the former 60 series R.J. ... Forest Innovation Quarter. Construction will begin immediately with plans ...
(Date:12/10/2014)... December 9, 2014   ... Platform   Jifflenow, ... scheduling solutions for business-to-business (B2B) events, today announced ... in mobile near-field communication (NFC), Bluetooth low energy ... (Logo: http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate ...
Breaking Biology News(10 mins):New telemetry implants expected to change how large animal toxicology studies are conducted 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... a group of hormones that includes cortisol, are considered ... their relationship to stress was first identified, it was ... to cope with the physical demands of stress. Subsequently, ... other stress-related disorders, giving rise to the hypothesis that ...
... (September 12, 2012) A remote park in northwest ... earth, according to the Wildlife Conservation Society (WCS), which ... there. The announcement was released at the IUCN ... through Sept. 13 in Jeju, South Korea. The ...
... Bio-IT World Expo Europe 2012 October ... http://photos.prnewswire.com/prnh/20120912/CG73074 ) The Fourth Annual Bio-IT ... informatics and IT professionals from across Europe and the ... four tracks: Clinical Genomics; Data Infrastructure and High Performance ...
Cached Biology News:Stress hormones: Good or bad for posttraumatic stress disorder risk? 2Amazing diversity documented in national park 2Global Biotech and Pharmaceutical Conference Early Bird Registration Discounts End This Week 2Global Biotech and Pharmaceutical Conference Early Bird Registration Discounts End This Week 3
Microlite 2+ Plate, round bottom; an irradiated, high binding surface with enhanced dynamic range, extra high reflectivity and minimal cross talk for low signal luminescent reactions....
Immulon 4 HBX 1x12 Strip, flat bottom; high binding extra surface with special resin and irradiation, offers maximum protein uptake....
... ultimate tool for both microplate reader ... two editions of SkanIt Software available; ... in life science research, and a ... for compliance with FDA's 21 CFR ...
Chicken polyclonal to UCK2 ( Abpromise for all tested applications). Antigen: Full length protein, corresponding to amino acids 1-261 of Human UCK2 Entrez Gene ID: 7371 Swiss Protein ID: ...
Biology Products: